Alpine Immune Sciences shares are trading higher after the company announced it presented the first clinical data of povetacicept in autoimmune glomerulonephritis during a late-breaking poster session at ASN Kidney Week.
Portfolio Pulse from Benzinga Newsdesk
Alpine Immune Sciences has presented the first clinical data of povetacicept in autoimmune glomerulonephritis at ASN Kidney Week, which has led to an increase in its share price.
November 02, 2023 | 5:04 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Alpine Immune Sciences' shares are trading higher after the company presented the first clinical data of povetacicept in autoimmune glomerulonephritis.
The presentation of the first clinical data of povetacicept in autoimmune glomerulonephritis by Alpine Immune Sciences has been positively received by the market, leading to an increase in the company's share price. This indicates a positive short-term impact on the company's stock.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100